Affordable Access

deepdyve-link
Publisher Website

Long-Term Outcomes of Transarterial Chemoembolization Combined with Radiofrequency Ablation Versus Transarterial Chemoembolization Alone for Recurrent Hepatocellular Carcinoma After Surgical Resection.

Authors
  • Song, Qingfeng1
  • Ren, Weizheng2
  • Fan, Liwei3
  • Zhao, Meiqi1
  • Mao, Lisha1
  • Jiang, Shichai1
  • Zhao, Chang3
  • Cui, Ying4
  • 1 Department of Medical Research, Affiliated Tumor Hospital of Guangxi Medical University, No. 22 Shuangyong Rd, Nanning, China. , (China)
  • 2 Department of Hepatobiliary Surgery, The First Medical Center, Chinese PLA General Hospital, Chinese PLA Medical School, Beijing, China. , (China)
  • 3 Department of Interventional Radiology, Affiliated Tumor Hospital of Guangxi Medical University, Nanning, China. , (China)
  • 4 Department of Medical Research, Affiliated Tumor Hospital of Guangxi Medical University, No. 22 Shuangyong Rd, Nanning, China. [email protected] , (China)
Type
Published Article
Journal
Digestive Diseases and Sciences
Publisher
Springer-Verlag
Publication Date
Apr 01, 2020
Volume
65
Issue
4
Pages
1266–1275
Identifiers
DOI: 10.1007/s10620-019-05733-0
PMID: 31312995
Source
Medline
Keywords
Language
English
License
Unknown

Abstract

There is lack of data for identifying optimal local therapy for the management of recurrent hepatocellular carcinoma (HCC) after hepatic resection. A retrospective study was performed to compare the effectiveness of transarterial chemoembolization (TACE) plus radiofrequency ablation (RFA) with that of TACE alone for recurrent HCC. From 2007 to 2013, patients with recurrent HCC ≤ 5 cm were treated with either TACE plus RFA (n = 96) or TACE (n = 63). Inverse probability of treatment weighting was used to make allowances for imbalances in treatment assignment. The disease-free survival (DFS) and overall survival (OS) were retrospectively analyzed. The TACE group had lower pretreatment Child-Pugh class (P = 0.025) and shorter pretreatment interval of recurrence (P = 0.028). The 1-, 3-, and 5-year DFS rates for the TACE-RFA group were 55.1%, 22.5%, and 9.7%, respectively, and 41.1%, 9.9%, and 4.9%, respectively, for the TACE group. The OS rates at 1, 3, and 5 years were 82.3%, 42.7%, and 16.5%, respectively, in the TACE-RFA group, and 75.9%, 30.7%, and 11.3%, respectively, in the TACE group. Cirrhosis was significantly associated with disease progression (hazard ratio [HR] 1.53; 95% CI 1.09-2.14; P = 0.014). In patients with recurrent HCC ≤ 5 cm, TACE-RFA shows better DFS than TACE alone as a first-line local therapy.

Report this publication

Statistics

Seen <100 times